Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice

Sara Gardenghi, Pedro Ramos, Maria Franca Marongiu, Luca Melchiori, Laura Breda, Ella Guy, Kristen Muirhead, Niva Rao, Cindy N. Roy, Nancy C. Andrews, Elizabeta Nemeth, Antonia Follenzi, Xiuli An, Narla Mohandas, Yelena Ginzburg, Eliezer A. Rachmilewitz, Patricia J. Giardina, Robert W. Grady, Stefano Rivella

Research output: Contribution to journalArticle

Abstract

Excessive iron absorption is one of the main features of β-thalassemia and can lead to severe morbidity and mortality. Serial analyses of β-thalassemic mice indicate that while hemoglobin levels decrease over time, the concentration of iron in the liver, spleen, and kidneys markedly increases. Iron overload is associated with low levels of hepcidin, a peptide that regulates iron metabolism by triggering degradation of ferroportin, an iron-transport protein localized on absorptive enterocytes as well as hepatocytes and macrophages. Patients with β-thalassemia also have low hepcidin levels. These observations led us to hypothesize that more iron is absorbed in β-thalassemia than is required for erythropoiesis and that increasing the concentration of hepcidin in the body of such patients might be therapeutic, limiting iron overload. Here we demonstrate that a moderate increase in expression of hepcidin in β-thalassemic mice limits iron overload, decreases formation of insoluble membrane-bound globins and reactive oxygen species, and improves anemia. Mice with increased hepcidin expression also demonstrated an increase in the lifespan of their red cells, reversal of ineffective erythropoiesis and splenomegaly, and an increase in total hemoglobin levels. These data led us to suggest that therapeutics that could increase hepcidin levels or act as hepcidin agonists might help treat the abnormal iron absorption in individuals with β-thalassemia and related disorders.

Original languageEnglish (US)
Pages (from-to)4466-4477
Number of pages12
JournalJournal of Clinical Investigation
Volume120
Issue number12
DOIs
StatePublished - Dec 1 2010

Fingerprint

Hepcidins
Iron Overload
Anemia
Thalassemia
Iron
Erythropoiesis
Therapeutics
Hemoglobins
Globins
Enterocytes
Splenomegaly
Hepatocytes
Reactive Oxygen Species
Carrier Proteins
Spleen
Macrophages
Morbidity
Kidney
Peptides
Membranes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gardenghi, S., Ramos, P., Marongiu, M. F., Melchiori, L., Breda, L., Guy, E., ... Rivella, S. (2010). Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. Journal of Clinical Investigation, 120(12), 4466-4477. https://doi.org/10.1172/JCI41717

Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. / Gardenghi, Sara; Ramos, Pedro; Marongiu, Maria Franca; Melchiori, Luca; Breda, Laura; Guy, Ella; Muirhead, Kristen; Rao, Niva; Roy, Cindy N.; Andrews, Nancy C.; Nemeth, Elizabeta; Follenzi, Antonia; An, Xiuli; Mohandas, Narla; Ginzburg, Yelena; Rachmilewitz, Eliezer A.; Giardina, Patricia J.; Grady, Robert W.; Rivella, Stefano.

In: Journal of Clinical Investigation, Vol. 120, No. 12, 01.12.2010, p. 4466-4477.

Research output: Contribution to journalArticle

Gardenghi, S, Ramos, P, Marongiu, MF, Melchiori, L, Breda, L, Guy, E, Muirhead, K, Rao, N, Roy, CN, Andrews, NC, Nemeth, E, Follenzi, A, An, X, Mohandas, N, Ginzburg, Y, Rachmilewitz, EA, Giardina, PJ, Grady, RW & Rivella, S 2010, 'Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice', Journal of Clinical Investigation, vol. 120, no. 12, pp. 4466-4477. https://doi.org/10.1172/JCI41717
Gardenghi, Sara ; Ramos, Pedro ; Marongiu, Maria Franca ; Melchiori, Luca ; Breda, Laura ; Guy, Ella ; Muirhead, Kristen ; Rao, Niva ; Roy, Cindy N. ; Andrews, Nancy C. ; Nemeth, Elizabeta ; Follenzi, Antonia ; An, Xiuli ; Mohandas, Narla ; Ginzburg, Yelena ; Rachmilewitz, Eliezer A. ; Giardina, Patricia J. ; Grady, Robert W. ; Rivella, Stefano. / Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. In: Journal of Clinical Investigation. 2010 ; Vol. 120, No. 12. pp. 4466-4477.
@article{16317e4432a64aafba63046d30b1a7d8,
title = "Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice",
abstract = "Excessive iron absorption is one of the main features of β-thalassemia and can lead to severe morbidity and mortality. Serial analyses of β-thalassemic mice indicate that while hemoglobin levels decrease over time, the concentration of iron in the liver, spleen, and kidneys markedly increases. Iron overload is associated with low levels of hepcidin, a peptide that regulates iron metabolism by triggering degradation of ferroportin, an iron-transport protein localized on absorptive enterocytes as well as hepatocytes and macrophages. Patients with β-thalassemia also have low hepcidin levels. These observations led us to hypothesize that more iron is absorbed in β-thalassemia than is required for erythropoiesis and that increasing the concentration of hepcidin in the body of such patients might be therapeutic, limiting iron overload. Here we demonstrate that a moderate increase in expression of hepcidin in β-thalassemic mice limits iron overload, decreases formation of insoluble membrane-bound globins and reactive oxygen species, and improves anemia. Mice with increased hepcidin expression also demonstrated an increase in the lifespan of their red cells, reversal of ineffective erythropoiesis and splenomegaly, and an increase in total hemoglobin levels. These data led us to suggest that therapeutics that could increase hepcidin levels or act as hepcidin agonists might help treat the abnormal iron absorption in individuals with β-thalassemia and related disorders.",
author = "Sara Gardenghi and Pedro Ramos and Marongiu, {Maria Franca} and Luca Melchiori and Laura Breda and Ella Guy and Kristen Muirhead and Niva Rao and Roy, {Cindy N.} and Andrews, {Nancy C.} and Elizabeta Nemeth and Antonia Follenzi and Xiuli An and Narla Mohandas and Yelena Ginzburg and Rachmilewitz, {Eliezer A.} and Giardina, {Patricia J.} and Grady, {Robert W.} and Stefano Rivella",
year = "2010",
month = "12",
day = "1",
doi = "10.1172/JCI41717",
language = "English (US)",
volume = "120",
pages = "4466--4477",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "12",

}

TY - JOUR

T1 - Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice

AU - Gardenghi, Sara

AU - Ramos, Pedro

AU - Marongiu, Maria Franca

AU - Melchiori, Luca

AU - Breda, Laura

AU - Guy, Ella

AU - Muirhead, Kristen

AU - Rao, Niva

AU - Roy, Cindy N.

AU - Andrews, Nancy C.

AU - Nemeth, Elizabeta

AU - Follenzi, Antonia

AU - An, Xiuli

AU - Mohandas, Narla

AU - Ginzburg, Yelena

AU - Rachmilewitz, Eliezer A.

AU - Giardina, Patricia J.

AU - Grady, Robert W.

AU - Rivella, Stefano

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Excessive iron absorption is one of the main features of β-thalassemia and can lead to severe morbidity and mortality. Serial analyses of β-thalassemic mice indicate that while hemoglobin levels decrease over time, the concentration of iron in the liver, spleen, and kidneys markedly increases. Iron overload is associated with low levels of hepcidin, a peptide that regulates iron metabolism by triggering degradation of ferroportin, an iron-transport protein localized on absorptive enterocytes as well as hepatocytes and macrophages. Patients with β-thalassemia also have low hepcidin levels. These observations led us to hypothesize that more iron is absorbed in β-thalassemia than is required for erythropoiesis and that increasing the concentration of hepcidin in the body of such patients might be therapeutic, limiting iron overload. Here we demonstrate that a moderate increase in expression of hepcidin in β-thalassemic mice limits iron overload, decreases formation of insoluble membrane-bound globins and reactive oxygen species, and improves anemia. Mice with increased hepcidin expression also demonstrated an increase in the lifespan of their red cells, reversal of ineffective erythropoiesis and splenomegaly, and an increase in total hemoglobin levels. These data led us to suggest that therapeutics that could increase hepcidin levels or act as hepcidin agonists might help treat the abnormal iron absorption in individuals with β-thalassemia and related disorders.

AB - Excessive iron absorption is one of the main features of β-thalassemia and can lead to severe morbidity and mortality. Serial analyses of β-thalassemic mice indicate that while hemoglobin levels decrease over time, the concentration of iron in the liver, spleen, and kidneys markedly increases. Iron overload is associated with low levels of hepcidin, a peptide that regulates iron metabolism by triggering degradation of ferroportin, an iron-transport protein localized on absorptive enterocytes as well as hepatocytes and macrophages. Patients with β-thalassemia also have low hepcidin levels. These observations led us to hypothesize that more iron is absorbed in β-thalassemia than is required for erythropoiesis and that increasing the concentration of hepcidin in the body of such patients might be therapeutic, limiting iron overload. Here we demonstrate that a moderate increase in expression of hepcidin in β-thalassemic mice limits iron overload, decreases formation of insoluble membrane-bound globins and reactive oxygen species, and improves anemia. Mice with increased hepcidin expression also demonstrated an increase in the lifespan of their red cells, reversal of ineffective erythropoiesis and splenomegaly, and an increase in total hemoglobin levels. These data led us to suggest that therapeutics that could increase hepcidin levels or act as hepcidin agonists might help treat the abnormal iron absorption in individuals with β-thalassemia and related disorders.

UR - http://www.scopus.com/inward/record.url?scp=78649813036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649813036&partnerID=8YFLogxK

U2 - 10.1172/JCI41717

DO - 10.1172/JCI41717

M3 - Article

C2 - 21099112

AN - SCOPUS:78649813036

VL - 120

SP - 4466

EP - 4477

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -